Basilea

(IN BRIEF) Basilea Pharmaceutica has received a CHF 1.7 million milestone payment from its partner Asahi Kasei Pharma following continued strong sales of Cresemba® in Japan—marking the second consecutive quarterly milestone. Cresemba, now marketed in over 70 countries, achieved USD … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of novel antifungal and antibacterial treatments. The agreement provides an initial USD 29 million, with the potential … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), achieved significant sales in Europe, triggering a USD 25 million milestone payment from partner Pfizer. This achievement highlights Cresemba’s strong performance in treating severe fungal infections. The milestone … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for ZEVTERA® (ceftobiprole medocaril sodium for injection). The approval covers its use in adult patients with Staphylococcus aureus bloodstream infections (bacteremia), … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) announced a significant milestone with a USD 1.25 million payment triggered by the robust sales performance of its antifungal medication, Cresemba® (isavuconazole), in the Asia Pacific region and China by its license partner … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) has announced that its partner Knight Therapeutics Inc. (TSX: GUD) exceeded the sales threshold for the antifungal Cresemba (isavuconazole) in Latin America in 2023, triggering the first sales milestone payment for the region. … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN), a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced an asset purchase agreement with Spexis AG (SIX: SPEX) for a preclinical antibiotics program aimed at combating Gram-negative bacteria, including … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company dedicated to addressing severe bacterial and fungal infections, has announced that its antifungal medication, Cresemba® (isavuconazole), has achieved robust sales performance in the Asia Pacific region and China through its licensing partner, … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced robust financial results for the first half-year ending June 30, 2023. Their CEO, David Veitch, highlighted the company’s progress in executing their … Read the full press release →

(NOTICIA EN BREVE) Biotalys y Syngenta Crop Protection se están asociando para investigar, desarrollar y comercializar soluciones de biocontrol para manejar plagas en una amplia gama de cultivos. La solución se basará en la plataforma tecnológica AGROBODY de Biotalys, que … Read the full press release →

(COMUNICADO DE PRENSA) BASEL, 12-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), un pionero mundial en productos farmacéuticos y diagnóstico centrado en el avance de la ciencia para mejorar la vida de las personas, ha anunciado que la … Read the full press release →

La compañía anuncia la aprobación de la FDA para sus ensayos de líquido cefalorraquídeo (LCR) para la enfermedad de Alzheimer Los ensayos Elecsys® para la enfermedad de Alzheimer (EA) en LCR estarán disponibles en los analizadores de inmunoensayo totalmente automatizados … Read the full press release →

Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX: BSLN), a commercial stage biopharmaceutical company, has announced the company has secured non-dilutive refinancing in the amount of CHF 75 … Read the full press release →

Annonce ad hoc conformément à l’art. 53LR (COMMUNIQUÉ DE PRESSE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX : BSLN), une société biopharmaceutique au stade commercial, a annoncé la La société a obtenu un refinancement non dilutif d’un montant … Read the full press release →

El compromiso renovado proporcionará tratamiento preventivo (profiláctico) continuo a hasta 1000 personas con hemofilia A en lugares donde hay poco o ningún acceso al tratamiento de la hemofilia. El tratamiento profiláctico tiene como objetivo prevenir las hemorragias y permitir que las personas … Read the full press release →

(COMUNICADO DE PRENSA) DÜBENDORF, 8-Feb-2022 — /EuropaWire/ — Empa, el instituto de investigación suizo para la ciencia y la tecnología aplicadas a los materiales, ha anunciado que su equipo de investigación ha demostrado cómo el uso de aerogeles como aislamiento … Read the full press release →

BASEL, 11-Dec-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) by Astellas Pharma Inc. (“Astellas”) in the United States exceeded the threshold triggering a milestone payment to Basilea in the amount of … Read the full press release →